TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07229313: A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Kivu Bioscience Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 76 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$879,648

Rescue Site Savings

+$565,488

Unlock Full NCT07229313 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07229313 Rescue Dossier →